Neurocrine's total assets for Q4 2025 were $4.63B, an increase of 8.58% from the previous quarter. NBIX total liabilities were $1.38B for the fiscal quarter, a 9.21% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.